Drug Trial Radar · NCT03720041
Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Jun 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
740
Planned (sponsor's estimate)
Start
Aug 4, 2020
Primary completion
Dec 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- University of LeedsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK; Takeda; Celgene
- First posted
- Oct 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Trial Title: FiTNEss (UK-MRA Myeloma XIV) - Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma Overview: A phase III, multi-centre, randomised controlled trial to compare standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with the novel triplet ixazomib, lenalidomide and dexamethasone (IRD), and to compare maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I) in patients with newly diagnosed multiple myeloma not suitable for a stem cell transplant. All participants receive induction treatment with ixazomib, lenalidomide and dexamethasone and are randomised on a 1:1 basis at trial entry to the use of frailty score-adjusted up-front dose reductions vs. standard up-front dosing followed by toxicity dependent reactive dose-modifications during therapy. Following 12 cycles of induction treatment participants alive and progression-free undergo a second randomisation on a 1:1 basis to maintenance treatment with lenalidomide plus placebo versus lenalidomide plus ixazomib. Participants and their treating physicians will be blinded to maintenance allocation. Participant population: * Newly diagnosed as having Multiple Myeloma (MM) according to the updated IMWG diagnostic criteria 2014 (see Appendix 1 for criteria) * Not eligible for stem cell transplant * Aged at least 18 years * Able to provide written informed consent Number of participants: 740 participants will be entered into the trial at Randomisation 1 (R1), with 478 participants at Randomisation 2 (R2). Objectives: The primary objectives of this study are to determine: * Early treatment cessation (within 60 days of randomisation) for standard versus frailty-adjusted up-front dosing * Progression-free survival (PFS, from maintenance randomisation) for lenalidomide + placebo (R) versus lenalidomide + ixazomib (R+I) The secondary objectives of this study are to assess progression-free survival (PFS) for standard versus frailty-adjusted up-front dosing reductions, time to progression, time to 2nd PFS event (PFS2), overall survival (OS), survival after progression, deaths within 12 months of R1, overall response rate (ORR), attainment of ≥VGPR, attainment of MRD negativity, duration of response, time to improved response, time to next treatment, treatment compliance and total amount of therapy delivered, toxicity \& safety including the incidence of SPMs, Quality of Life (QoL), cost effectiveness of standard versus frailty-adjusted up-front dosing of IRD and cost-effectiveness of R + I versus R. Exploratory objectives are prospective validation of a novel frailty risk score (UK-MRA Myeloma Risk Profile - MRP), usefulness of Karnofsky Performance Status (PS), and association of molecular subgroups with response, PFS and OS.
Conditions
- Multiple Myeloma
Interventions
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive armDrug
In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses: Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg/day on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged \> 75 years; taken orally Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days.
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive armDrug
In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below: 1. Fit category: Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally 2. Unfit category: Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally 3. Frail category: Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days.
R2: Lenalidomide plus placebo maintenanceDrug
Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses: Lenalidomide: 10mg\*/day on days 1-21, taken orally Placebo: 4mg\*/day on days 1, 8 and 15 \* or final dose administered at the end of induction treatment if lower. This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days. Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation.
R2: Lenalidomide + ixazomib maintenanceDrug
Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses: Lenalidomide: 10mg\*/day on days 1-21, taken orally Ixazomib: 4mg\*/day on days 1, 8 and 15 \* or final dose administered at the end of induction treatment if lower. This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days. Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Randomisation 1: Number of participants with early treatment cessationTime frame: Within 60 days of Randomisation 1
- Randomisation 2: Progression-free survival (PFS-R2)Time frame: The time from the date of Randomisation 2 to the date of first documented evidence of disease progression or death from any cause, up to 120 months
Locations
110 sites in 1 country. Site status is shown where the registry gives one.
Aberdeen Royal Infirmary
Aberdeen, United Kingdom · Recruiting
Nevill Hall Hospital
Abergavenny, United Kingdom · Not yet recruiting
Wrightington Hosptial
Appley Bridge, United Kingdom · Not yet recruiting
Ysbyty Gwynedd
Bangor, United Kingdom · Not yet recruiting
North Devon District Hospital
Barnstaple, United Kingdom · Not yet recruiting
Furness General Hospital
Barrow in Furness, United Kingdom · Not yet recruiting
Basingstoke and North Hampshire Hospital
Basingstoke, United Kingdom · Not yet recruiting
Royal United Hospital
Bath, United Kingdom · Not yet recruiting
Belfast City Hospital
Belfast, United Kingdom · Not yet recruiting
Birmingham Heartlands Hospital
Birmingham, United Kingdom · Not yet recruiting
Queen Elizabeth Hospital
Birmingham, United Kingdom · Not yet recruiting
Royal Blackburn Hospital
Blackburn, United Kingdom · Not yet recruiting
Blackpool Victoria Hospital
Blackpool, United Kingdom · Recruiting
Royal Bolton Hospital
Bolton, United Kingdom · Not yet recruiting
Pilgrim Hospital
Boston, United Kingdom · Not yet recruiting
Royal Bournemouth Hospital
Bournemouth, United Kingdom · Recruiting
Bradford Royal Infirmary
Bradford, United Kingdom · Not yet recruiting
Bristol Haematology and Oncology Centre
Bristol, United Kingdom · Recruiting
Southmead Hospital
Bristol, United Kingdom · Not yet recruiting
Queen's Hospital
Burton-on-Trent, United Kingdom · Not yet recruiting
Kent and Canterbury Hospital
Canterbury, United Kingdom · Recruiting
Chelmsford & Essex Hospital
Chelmsford, United Kingdom · Not yet recruiting
Cheltenham General Hospital
Cheltenham, United Kingdom · Recruiting
Countess of Chester Hospital
Chester, United Kingdom · Not yet recruiting
St Richard's Hospital
Chichester, United Kingdom · Not yet recruiting
Colchester General Hospital
Colchester, United Kingdom · Not yet recruiting
University Hospital Coventry
Coventry, United Kingdom · Not yet recruiting
Croydon University Hospital
Croydon, United Kingdom · Not yet recruiting
Royal Derby Hospital
Derby, United Kingdom · Not yet recruiting
Dorset County Hospital
Dorchester, United Kingdom · Not yet recruiting
Russells Hall Hospital
Dudley, United Kingdom · Not yet recruiting
Ninewells Hospital
Dundee, United Kingdom · Not yet recruiting
Western General Hospital
Edinburgh, United Kingdom · Not yet recruiting
Royal Devon & Exeter Hospital
Exeter, United Kingdom · Not yet recruiting
Medway Maritime Hospital
Gillingham, United Kingdom · Not yet recruiting
Gloucestershire Royal Hospital
Gloucester, United Kingdom · Not yet recruiting
Grantham and District Hospital
Grantham, United Kingdom · Not yet recruiting
Diana Princess of Wales Hospital
Grimsby, United Kingdom · Not yet recruiting
Royal Surrey County Hospital
Guildford, United Kingdom · Not yet recruiting
Calderdale Royal Hospital
Halifax, United Kingdom · Not yet recruiting
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.